Sign up
Pharma Capital

Futura Medical fully funded and on track with critical erectile dysfunction trial

Futura Medical PLC's (LON:FUM) CEO James Barder tells Proactive London they're on track to deliver the results from their phase III trial for a fast-acting gel for erectile dysfunction (ED) by the end of the year.

The first of two studies of MED2005 got underway in October treating 1,000 men at 60 centres across Europe.

A recent shift in strategy at Futura's seen them now focus attention firmly on MED2005, the ED treatment and TPR100, a topical non-steroidal anti-inflammatory and pain killer.


View full FUM profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.